Promoting investigational therapies as if they are already approved by FDA may seem like a bright-line violation but even some well-respected companies have crossed it. The latest firm to receive a rebuke on this score from FDA’s Office of Prescription Drug Promotion (OPDP), Burzynski Research Institute, has a more colorful history than most.
In an Oct. 18 “notice of violation” letter, OPDP cites Burzynski for press releases claiming, for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?